← Eichor
Condition: Measurable Residual Disease Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Measurable Residual Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequenti
Phase 2 · 11 location(s) · SCRI Development Innovations, LLC · NCT06974786ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC
Phase N/A · 1 location(s) · Fang Wu · NCT05198154Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Phase 2 · 7 location(s) · Abramson Cancer Center at Penn Medicine · NCT04841148Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
NA · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT07025785European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07356882A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia:
Phase 1/Phase 2 · 2 location(s) · Jacqueline Garcia, MD · NCT07148180GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
Phase N/A · 15 location(s) · Claus Lindbjerg Andersen · NCT06111105Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT05867901cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Phase N/A · 17 location(s) · Adela, Inc · NCT05366881To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07291921Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper
Phase N/A · 1 location(s) · RenJi Hospital · NCT05595408Better Leukemia Diagnostics Through AI (BELUGA)
Phase N/A · 1 location(s) · Munich Leukemia Laboratory · NCT04466059CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Phase 3 · 1 location(s) · Peking University People's Hospital · NCT07441291MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06498752Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Phase 2 · 1 location(s) · Rong Tao · NCT07507318A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Co
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07136077A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06773208Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopo
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05091372ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer
Phase 2 · 1 location(s) · University of Miami · NCT06902272French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
Phase N/A · 2 location(s) · University Hospital, Montpellier · NCT06287723Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Phase 2 · 14 location(s) · Grupo Cooperativo de Estudio y Tratamiento de las Leucemias · NCT06668558Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO
Phase 3 · 49 location(s) · Fondazione Italiana Linfomi - ETS · NCT05929222Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"
Phase 2 · 1 location(s) · Tata Memorial Centre · NCT07021677HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
Phase 1 · 1 location(s) · University of Illinois at Chicago · NCT05192122Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
Phase 3 · 3 location(s) · Seoul National University Hospital · NCT05534087Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT07524114Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-na
Phase 2 · 1 location(s) · Paolo Ghia · NCT04758975Discontinuation Study
NA · 1 location(s) · University College Cork · NCT05866757MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
Phase 2 · 6 location(s) · Peter MacCallum Cancer Centre, Australia · NCT06414148
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.